Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomised, Non-inferiority Study of Chloroprocaine 2% and the Active Control Ropivacaine 0.75% (AstraZeneca) in Ultrasound-guided Axillary Nerve Block for Short-duration Distal Upper Limb Surgery

NCT02385097 is registered in ClinicalTrials.gov with Sintetica SA as lead sponsor.

NCT NCT02385097
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02385097 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomised, Non-inferiority Study of Chloroprocaine 2% and the Active Control Ropivacaine 0.75% (AstraZeneca) in Ultrasound-guided Axillary Nerve Block for Short-duration Distal Upper Limb Surgery
Lead sponsor
Sintetica SA
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2015
Completion date
May 31, 2017
Enrollment
211 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

axillary nerve block